Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 28, 2018

View Archived Issues

Aldeyra Therapeutics, Janssen enter systemic inflammatory disease collaboration

BMS licenses Domain Therapeutics' bioSens-All technology

IL17F His161Arg gene polymorphism found positively associated with psoriasis

EMA grants orphan drug designation to cannabidiol for tuberous sclerosis

Beacon Discovery enters GPCR drug discovery collaboration with Takeda

Intensity Therapeutics reports data from phase I/II study of INT-230-6

EMA gives accelerated assessment to Shire's lanadelumab

Mannose-binding lectin tied to influenza-associated critical illness in children

Cereblon gene knockout mimics autosomal recessive non-syndromic intellectual disability

PhaseBio Pharmaceuticals receives NIH grant to support PB-1046 development

Dyadic enters funded proof-of-concept research collaboration with Mitsubishi Tanabe

Novo Nordisk submits regulatory applications for N8-GP in U.S. and E.U.

Dendritic cell-based DNA vaccine effectively protects against herpes simplex virus keratitis in vivo

FDA accepts Tetraphase's NDA for eravacycline

Orphelia Pharma announces MAA filing for Kigabeq

Ophthotech, University of Massachusetts collaborate on novel gene therapies for ophthalmic diseases

Shanghai De Novo Pharmatech divulges new IDO1 inhibitors

Cynata reports updated data from phase I trial of CYP-001 in steroid-resistant GvHD

European Commission approves Hemlibra

Zafgen presents novel MetAP 2 inhibitors

RWTH Aachen discloses novel ATR kinase inhibitors

FDA accepts Shire's BLA for calaspargase pegol

Quentis Therapeutics completes series A financing to advance first-in-class immunotherapies

SK Chemicals and Sanofi patent vaccine compositions for streptococcal infection

Reata updates timeline for bardoxolone methyl studies in rare forms of chronic kidney disease

Senti Biosciences closes series A financing to develop gene and cell-based therapies

Novel anti-PD-1 antibodies presented by Y-Biologics

Abbott and Surmodics enter agreement for SurVeil drug-coated balloon

Phase III study of Hisamitsu's HP-3000 transdermal patch meets primary endpoint

Celgene receives FDA refusal to file letter for ozanimod NDA in relapsing MS

TRPM4 gene polymorphisms associated with cerebral edema in TBI patients

Reminder -- we want your opinion on TRDN

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...